Tocilizumab biosimilar (Celltrion)

托珠单抗生物类似药 (Celltrion)

Report date: 2025/03/19 16:04:14

Base Information

Drug NameTocilizumab biosimilar (Celltrion)
Drug Alias Nametocilizumab-anohAvtozmaCT-P47CT-P-47
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[6] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/01/24
Country/TerritoryUnited StatesPolandSouth Korea +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare Hungary KftCelltrion Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AC07
Related LinksN/A